RxDoctor Payments Data

Naeem Rahim, MD

Nephrology · Chubbuck, IDNPI 1235286808

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novartis at 25.1% of the total. 2025 is the largest year on record at $175, more than ten times the $17 reported in 2019.

$696in general payments, 2019–2025

Across 24 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$174
  • AstraZeneca$106
  • Vifor Pharma, Inc.$103
  • Fresenius USA Marketing, Inc.$57
  • Travere Therapeutics, Inc.$53
  • Amgen$52
  • plus $151 from 5 others

What the payments were for

  • Food & beverage$69299%
  • Education$41%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$696 in reported general payments places this provider in the 80th percentile of 30 nephrology providers in Idaho.

See all nephrology providers in Idaho

Medicare billing

Part B allowed, 2024
$178,514
Medicare patients
363
Services billed
1,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol71$57,530
LokelmaSodium Zirconium Cyclosilicate11$12,980
Sevelamer Carbonate45$5,355
Midodrine Hcl14$3,485
Calcitriol215$2,832
Tacrolimus29$2,667
Gentamicin Sulfate41$1,907
Clonidine13$1,714
Losartan Potassium227$1,577
Metoprolol Succinate58$837
Allopurinol88$709
Torsemide29$677
Hydralazine Hcl28$596
Spironolactone43$469
Carvedilol70$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$106$70,51082 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 30 nephrology providers in Idaho.

Other nephrology in Chubbuck

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →